Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its PDUFA date, the agency approved the firm’s first-line breast cancer treatment ...

马萨诸塞州贝德福德 - 专注于开发眼科疾病治疗方案的生物制药公司Ocular Therapeutix, Inc. (NASDAQ: OCUL)宣布任命Namrata Saroj博士为首席业务官。Saroj博士在眼科药物开发领域拥有超过20年的经验，自2024年2月起一直担任公司的开发战略顾问，现将全职加入领导团队。 Saroj博士的职业生涯包括对主要FDA批准的眼科药物（如LUCENTIS®和EY ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results. "This is ...

生物技术公司Adaptimmune Therapeutics PLC (NASDAQ:ADAP)周五收到纳斯达克的通知，称该公司不符合最低投标价格要求。该公司的美国存托凭证（ADS）连续30个交易日的交易价格低于1.00美元的门槛，违反了纳斯达克上市规则5450 (a) (1)。

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

https://www.tipranks.com/news/the-fly/stryker-price-target-raised-to-400-from-360-at-canaccord Genentech, a member of the Roche (RHHBY), announced topline one-year ...

Application error: a client-side exception has occurred (see the browser console for more information).

Reports Q3 revenue $29.4M, consensus $26.55M. “This is a pivotal time for Sangamo (SGMO) as we build upon our recent strong momentum with ...